SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$95M+11.1% YoY

Gross Profit

$91M95.6% margin

Operating Income

$29M30.5% margin

Net Income

$22M22.7% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

-5.4%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$576M

Stockholders' Equity

$613M

Cash & Equivalents

$226M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$85M	+11.1%
Gross Profit	$91M	$82M	+11.0%
Operating Income	$29M	$25M	+14.1%
Net Income	$22M	$18M	+17.3%

Revenue Segments

Product

$92M78%

Oxtellar X R

$24M20%

Royalty

$2M2%

SUPN Q1 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena